Cyclophosphamide - Accentia Biopharmaceuticals/Biovest International

Drug Profile

Cyclophosphamide - Accentia Biopharmaceuticals/Biovest International

Alternative Names: Cyrevia; HiCy

Latest Information Update: 11 Sep 2013

Price : $50

At a glance

  • Originator Johns Hopkins University School of Medicine
  • Developer Accentia Biopharmaceuticals; Biovest International
  • Class Antineoplastics; Antirheumatics; Cyclophosphamides; Myeloablative agonists; Small molecules
  • Mechanism of Action Alkylating agents; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease; Autoimmune haemolytic anaemia; Systemic scleroderma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Multiple sclerosis; Transplant rejection

Most Recent Events

  • 11 Sep 2013 Discontinued - Preclinical for Transplant rejection in USA (IV)
  • 11 Sep 2013 Discontinued - Preclinical for Multiple sclerosis in USA (IV)
  • 14 Sep 2011 Cyrevia™ receives Orphan Drug status for Graft-versus-host disease in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top